Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Research & Development (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Research & Development for 8 consecutive years, with $84.1 million as the latest value for Q1 2026.

  • Quarterly Research & Development rose 20.78% to $84.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $331.4 million through Feb 2026, up 37.34% year-over-year, with the annual reading at $316.9 million for FY2025, 42.99% up from the prior year.
  • Research & Development for Q1 2026 was $84.1 million at Nurix Therapeutics, up from $83.0 million in the prior quarter.
  • The five-year high for Research & Development was $86.1 million in Q3 2025, with the low at $43.1 million in Q1 2022.
  • Average Research & Development over 5 years is $58.6 million, with a median of $49.7 million recorded in 2023.
  • The sharpest move saw Research & Development skyrocketed 87.53% in 2022, then decreased 3.64% in 2023.
  • Over 5 years, Research & Development stood at $46.1 million in 2022, then rose by 7.82% to $49.7 million in 2023, then surged by 35.22% to $67.2 million in 2024, then grew by 23.5% to $83.0 million in 2025, then grew by 1.34% to $84.1 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $84.1 million, $83.0 million, and $86.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.